Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Rankings
59 current ranking rows (latest year per scope; 816 earlier yearly snapshots are on the ranking pages). Each row lists the scope, the formula version, the value and the exact inputs that produced it.
| Metric | Scope | Rank / eligible | Δ | Value | Percentile | Confidence | Formula | Generated | Inputs |
|---|---|---|---|---|---|---|---|---|---|
| Age-standardized incidence rate | USA · both sexes · all ages · 2023 · top-level cancers | #1 / 24 | = | 71.3 per 100,000 | 100 | High confidence | ci-asir-v1 | Sep 29, 2026 | showformula: epidemiology_observations.value WHERE metric = as_incidence_rate (standard_population fixed per scope)
inputs hash b755ca35e68b729c8dc63070 Trace lineage (admin) |
| Age-standardized incidence rate | USA · Female · all ages · 2023 · top-level cancers | #1 / 29 | = | 135.2 per 100,000 | 100 | High confidence | ci-asir-v1 | Sep 29, 2026 | showformula: epidemiology_observations.value WHERE metric = as_incidence_rate (standard_population fixed per scope)
inputs hash 4d01732d23418d0cca033d77 Trace lineage (admin) |
| Age-standardized incidence rate | USA · Male · all ages · 2023 · top-level cancers | #22 / 27 | = | 1.3 per 100,000 | 19.2 | High confidence | ci-asir-v1 | Sep 29, 2026 | showformula: epidemiology_observations.value WHERE metric = as_incidence_rate (standard_population fixed per scope)
inputs hash dbeda648a4f2a0068318f6d1 Trace lineage (admin) |
| Age-standardized mortality rate | USA · both sexes · all ages · 2024 · top-level cancers | #3 / 23 | = | 10.2 per 100,000 | 90.9 | High confidence | ci-asmr-v1 | Sep 29, 2026 | showformula: epidemiology_observations.value WHERE metric = as_mortality_rate (standard_population fixed per scope)
inputs hash 075bdb903aa37f48ae5b75b4 Trace lineage (admin) |
| Age-standardized mortality rate | USA · Female · all ages · 2024 · top-level cancers | #2 / 28 | = | 18.7 per 100,000 | 96.3 | High confidence | ci-asmr-v1 | Sep 29, 2026 | showformula: epidemiology_observations.value WHERE metric = as_mortality_rate (standard_population fixed per scope)
inputs hash cd5df15b22c08f77ce10639c Trace lineage (admin) |
| Age-standardized mortality rate | USA · Male · all ages · 2024 · top-level cancers | #20 / 26 | ▲ 4 | 0.3 per 100,000 | 24 | High confidence | ci-asmr-v1 | Sep 29, 2026 | showformula: epidemiology_observations.value WHERE metric = as_mortality_rate (standard_population fixed per scope)
inputs hash 9f37d571bb39dc7855fa4d55 Trace lineage (admin) |
| Annual deaths | USA · both sexes · all ages · 2024 · top-level cancers | #3 / 31 | = | 43,897 count | 93.3 | High confidence | ci-mortality-count-v1 | Sep 29, 2026 | showformula: epidemiology_observations.value WHERE metric = mortality_count
inputs hash eda90f606aa05f603e206877 Trace lineage (admin) |
| Annual deaths | USA · Female · all ages · 2024 · top-level cancers | #2 / 28 | = | 43,402 count | 96.3 | High confidence | ci-mortality-count-v1 | Sep 29, 2026 | showformula: epidemiology_observations.value WHERE metric = mortality_count
inputs hash 10479f4404c381a0461a96b6 Trace lineage (admin) |
| Annual deaths | USA · Male · all ages · 2024 · top-level cancers | #22 / 26 | ▲ 4 | 495 count | 16 | High confidence | ci-mortality-count-v1 | Sep 29, 2026 | showformula: epidemiology_observations.value WHERE metric = mortality_count
inputs hash 0338faa988571e3aeb36ce8d Trace lineage (admin) |
| Annual new cases | USA · both sexes · all ages · 2023 · top-level cancers | #1 / 32 | = | 291,057 count | 100 | High confidence | ci-incidence-count-v1 | Sep 29, 2026 | showformula: epidemiology_observations.value WHERE metric = incidence_count
inputs hash a22c4753e0a7e00ce4e210b1 Trace lineage (admin) |
| Annual new cases | USA · Female · all ages · 2023 · top-level cancers | #1 / 29 | = | 288,494 count | 100 | High confidence | ci-incidence-count-v1 | Sep 29, 2026 | showformula: epidemiology_observations.value WHERE metric = incidence_count
inputs hash be481a61ede7e4e6eff7e04e Trace lineage (admin) |
| Annual new cases | USA · Male · all ages · 2023 · top-level cancers | #22 / 27 | = | 2,563 count | 19.2 | High confidence | ci-incidence-count-v1 | Sep 29, 2026 | showformula: epidemiology_observations.value WHERE metric = incidence_count
inputs hash faf268f2311c0e2f45598554 Trace lineage (admin) |
| Mortality-to-incidence ratio | USA · both sexes · all ages · 2023 · top-level cancers | #25 / 31 | = | 0.15 ratio | 20 | High confidence | ci-mir-v1 | Sep 29, 2026 | showformula: mortality_count / incidence_count (same geography, year, sex, source family)
inputs hash 4850aed222cf5b82949f3250 Trace lineage (admin) |
| Mortality-to-incidence ratio | USA · Female · all ages · 2023 · top-level cancers | #24 / 28 | = | 0.15 ratio | 14.8 | High confidence | ci-mir-v1 | Sep 29, 2026 | showformula: mortality_count / incidence_count (same geography, year, sex, source family)
inputs hash 6256cbc77f64879a8ded9826 Trace lineage (admin) |
| Mortality-to-incidence ratio | USA · Male · all ages · 2023 · top-level cancers | #19 / 26 | = | 0.2 ratio | 28 | High confidence | ci-mir-v1 | Sep 29, 2026 | showformula: mortality_count / incidence_count (same geography, year, sex, source family)
inputs hash 4fbc8d78eb3f4392ae965953 Trace lineage (admin) |
| Curated clinical evidence items | World · both sexes · all ages · latest · all malignant entities | #23 / 492 | = | 310 count | 95.5 | Medium confidence | ci-civic-evidence-v1 | Sep 29, 2026 | showformula: COUNT(civic_evidence_items) WHERE status = ACCEPTED AND cancer_id IN descendants(cancer)
inputs hash 00ec4259c26ee135c931f5a6 Trace lineage (admin) |
| Curated clinical evidence items | World · both sexes · all ages · latest · top-level cancers | #3 / 28 | = | 310 count | 92.6 | Medium confidence | ci-civic-evidence-v1 | Sep 29, 2026 | showformula: COUNT(civic_evidence_items) WHERE status = ACCEPTED AND cancer_id IN descendants(cancer)
inputs hash bc8c48b7174cc05d41e44bad Trace lineage (admin) |
| Genes with curated or cohort evidence | World · both sexes · all ages · latest · all malignant entities | #75 / 521 | = | 278 count | 85.8 | Medium confidence | ci-genes-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT gene) FROM (civic accepted evidence ∪ gdc frequency ≥ 0.05 AND cases_affected ≥ 20)
inputs hash dc02edfbbd5b601934401df4 Trace lineage (admin) |
| Genes with curated or cohort evidence | World · both sexes · all ages · latest · top-level cancers | #10 / 30 | = | 278 count | 69 | Medium confidence | ci-genes-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT gene) FROM (civic accepted evidence ∪ gdc frequency ≥ 0.05 AND cases_affected ≥ 20)
inputs hash 310f15666b06921ed2f70861 Trace lineage (admin) |
| Public genomic cohorts | World · both sexes · all ages · latest · all malignant entities | #27 / 296 | = | 32 count | 91.2 | Medium confidence | ci-cohorts-v1 | Sep 29, 2026 | showformula: COUNT(genomic_cohorts) WHERE cancer_id IN descendants(cancer)
inputs hash 401b2e31f9813fbae9c90ab7 Trace lineage (admin) |
| Public genomic cohorts | World · both sexes · all ages · latest · top-level cancers | #2 / 27 | = | 32 count | 96.2 | Medium confidence | ci-cohorts-v1 | Sep 29, 2026 | showformula: COUNT(genomic_cohorts) WHERE cancer_id IN descendants(cancer)
inputs hash f487d091433304c229ee188b Trace lineage (admin) |
| Publications, last 12 months | World · both sexes · all ages · latest · all malignant entities | #3 / 2,294 | = | 27,734 count | 99.9 | Medium confidence | ci-pubs-12m-v1 | Sep 29, 2026 | showformula: literature_counts.count WHERE window_key = 12m
inputs hash 6636ad9f834652e029647409 Trace lineage (admin) |
| Publications, last 12 months | World · both sexes · all ages · latest · top-level cancers | #1 / 36 | = | 27,734 count | 100 | Medium confidence | ci-pubs-12m-v1 | Sep 29, 2026 | showformula: literature_counts.count WHERE window_key = 12m
inputs hash 09e4f7aeda6ce8f572cc37f7 Trace lineage (admin) |
| Publications, last 5 years | World · both sexes · all ages · latest · all malignant entities | #5 / 2,873 | = | 133,010 count | 99.9 | Medium confidence | ci-pubs-5y-v1 | Sep 29, 2026 | showformula: literature_counts.count WHERE window_key = 5y (query stored per row)
inputs hash 531d42217f151c0dd79899a6 Trace lineage (admin) |
| Publications, last 5 years | World · both sexes · all ages · latest · top-level cancers | #1 / 36 | = | 133,010 count | 100 | Medium confidence | ci-pubs-5y-v1 | Sep 29, 2026 | showformula: literature_counts.count WHERE window_key = 5y (query stored per row)
inputs hash 8a115533edc694931ad082be Trace lineage (admin) |
| Publication growth | World · both sexes · all ages · latest · all malignant entities | #111 / 286 | = | 1.21 ratio | 61.4 | Medium confidence | ci-pub-growth-v1 | Sep 29, 2026 | showformula: publications_12m / (publications_5y_prior / 5)
inputs hash 3385afecab0ace04e61b6db0 Trace lineage (admin) |
| Publication growth | World · both sexes · all ages · latest · top-level cancers | #9 / 36 | = | 1.21 ratio | 77.1 | Medium confidence | ci-pub-growth-v1 | Sep 29, 2026 | showformula: publications_12m / (publications_5y_prior / 5)
inputs hash 402d29deeb47adac5c955a64 Trace lineage (admin) |
| Trial registration growth (year over year) | World · both sexes · all ages · latest · all malignant entities | #39 / 186 | = | 0.23 ratio | 79.5 | High confidence | ci-trial-growth-v1 | Sep 29, 2026 | showformula: (new_trials_12m − new_trials_prior_12m) / new_trials_prior_12m (first_posted_date windows; interventional; descendants)
|
| Trial registration growth (year over year) | World · both sexes · all ages · latest · top-level cancers | #1 / 24 | = | 0.23 ratio | 100 | High confidence | ci-trial-growth-v1 | Sep 29, 2026 | showformula: (new_trials_12m − new_trials_prior_12m) / new_trials_prior_12m (first_posted_date windows; interventional; descendants)
|
| Active clinical trials | World · both sexes · all ages · latest · all malignant entities | #13 / 1,654 | = | 2,627 count | 99.3 | Medium confidence | ci-active-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) FROM trial_conditions JOIN clinical_trials WHERE cancer_id IN descendants(cancer) AND study_type = INTERVENTIONAL AND overall_status IN (RECRUITING, NOT_YET_RECRUITING, ENROLLING_BY_INVITATION, ACTIVE_NOT_RECRUITING)
inputs hash f2f5ed2084d93bba6dcb810e Trace lineage (admin) |
| Active clinical trials | World · both sexes · all ages · latest · top-level cancers | #2 / 36 | = | 2,627 count | 97.1 | Medium confidence | ci-active-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) FROM trial_conditions JOIN clinical_trials WHERE cancer_id IN descendants(cancer) AND study_type = INTERVENTIONAL AND overall_status IN (RECRUITING, NOT_YET_RECRUITING, ENROLLING_BY_INVITATION, ACTIVE_NOT_RECRUITING)
inputs hash 36db18bc2db682c45dedd597 Trace lineage (admin) |
| Active Phase III trials | World · both sexes · all ages · latest · all malignant entities | #14 / 810 | = | 320 count | 98.4 | Medium confidence | ci-phase3-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) … active statuses AND PHASE3 = ANY(phases)
inputs hash 56fba75197c8c0044b9e345f Trace lineage (admin) |
| Active Phase III trials | World · both sexes · all ages · latest · top-level cancers | #2 / 36 | = | 320 count | 97.1 | Medium confidence | ci-phase3-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) … active statuses AND PHASE3 = ANY(phases)
inputs hash 7e874e202ec3e68f4c4a2534 Trace lineage (admin) |
| Recruiting clinical trials | World · both sexes · all ages · latest · all malignant entities | #13 / 1,277 | = | 1,396 count | 99.1 | Medium confidence | ci-recruiting-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) … overall_status = RECRUITING AND study_type = INTERVENTIONAL
inputs hash 4352f89d0670b61272a585b3 Trace lineage (admin) |
| Recruiting clinical trials | World · both sexes · all ages · latest · top-level cancers | #2 / 36 | = | 1,396 count | 97.1 | Medium confidence | ci-recruiting-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) … overall_status = RECRUITING AND study_type = INTERVENTIONAL
inputs hash e254423b3e4889483596cf7d Trace lineage (admin) |
| Recruiting Phase III trials | World · both sexes · all ages · latest · all malignant entities | #14 / 585 | = | 150 count | 97.8 | High confidence | ci-phase3-recruiting-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) … overall_status = RECRUITING AND PHASE3 = ANY(phases) AND study_type = INTERVENTIONAL
inputs hash ada23aaf0a7d803bc6e67424 Trace lineage (admin) |
| Recruiting Phase III trials | World · both sexes · all ages · latest · top-level cancers | #2 / 33 | = | 150 count | 96.9 | High confidence | ci-phase3-recruiting-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) … overall_status = RECRUITING AND PHASE3 = ANY(phases) AND study_type = INTERVENTIONAL
inputs hash 284e53e9bc6e51772da0f4e8 Trace lineage (admin) |
| Sponsor concentration (HHI) | World · both sexes · all ages · latest · all malignant entities | #599 / 615 | = | 0.006 index (0–1) | 2.6 | High confidence | ci-sponsor-hhi-v1 | Sep 29, 2026 | showformula: Σ (active_trials_by_lead_sponsor / active_trials)² over the cancer and its descendants
|
| Sponsor concentration (HHI) | World · both sexes · all ages · latest · top-level cancers | #33 / 36 | = | 0.006 index (0–1) | 8.6 | High confidence | ci-sponsor-hhi-v1 | Sep 29, 2026 | showformula: Σ (active_trials_by_lead_sponsor / active_trials)² over the cancer and its descendants
|
| Trial termination share | World · both sexes · all ages · latest · all malignant entities | #420 / 454 | = | 0.26 ratio | 7.5 | High confidence | ci-trial-termination-v1 | Sep 29, 2026 | showformula: (terminated + withdrawn) / (completed + terminated + withdrawn) WHERE first_posted_date ≥ 2010-01-01 AND study_type = INTERVENTIONAL
|
| Trial termination share | World · both sexes · all ages · latest · top-level cancers | #30 / 34 | = | 0.26 ratio | 12.1 | High confidence | ci-trial-termination-v1 | Sep 29, 2026 | showformula: (terminated + withdrawn) / (completed + terminated + withdrawn) WHERE first_posted_date ≥ 2010-01-01 AND study_type = INTERVENTIONAL
|
| Active trials per 1,000 annual deaths | USA · both sexes · all ages · 2024 · top-level cancers | #12 / 35 | = | 59.8 per 1,000 deaths | 67.6 | High confidence | ci-trials-per-deaths-v1 | Sep 29, 2026 | showformula: active_trials / (mortality_count / 1000) (same geography, year, sex, source family; deaths ≥ 100)
|
| Active trials per 1,000 annual deaths | USA · Female · all ages · 2024 · top-level cancers | #24 / 32 | = | 60.5 per 1,000 deaths | 25.8 | High confidence | ci-trials-per-deaths-v1 | Sep 29, 2026 | showformula: active_trials / (mortality_count / 1000) (same geography, year, sex, source family; deaths ≥ 100)
|
| Active trials per 1,000 annual deaths | USA · Male · all ages · 2024 · top-level cancers | #1 / 30 | = | 5,307.1 per 1,000 deaths | 100 | Medium confidence | ci-trials-per-deaths-v1 | Sep 29, 2026 | showformula: active_trials / (mortality_count / 1000) (same geography, year, sex, source family; deaths ≥ 100)
|
| Publications (5 y) per 1,000 annual deaths | USA · both sexes · all ages · 2024 · top-level cancers | #5 / 35 | = | 3,030 per 1,000 deaths | 88.2 | High confidence | ci-pubs-per-deaths-v1 | Sep 29, 2026 | showformula: publications_5y / (mortality_count / 1000) (same geography, year, sex, source family; deaths ≥ 100)
|
| Publications (5 y) per 1,000 annual deaths | USA · Female · all ages · 2024 · top-level cancers | #13 / 32 | = | 3,064.6 per 1,000 deaths | 61.3 | High confidence | ci-pubs-per-deaths-v1 | Sep 29, 2026 | showformula: publications_5y / (mortality_count / 1000) (same geography, year, sex, source family; deaths ≥ 100)
|
| Publications (5 y) per 1,000 annual deaths | USA · Male · all ages · 2024 · top-level cancers | #1 / 30 | = | 268,707.1 per 1,000 deaths | 100 | Medium confidence | ci-pubs-per-deaths-v1 | Sep 29, 2026 | showformula: publications_5y / (mortality_count / 1000) (same geography, year, sex, source family; deaths ≥ 100)
|
| Research Gap Index | USA · both sexes · all ages · 2024 · top-level cancers | #22 / 31 | ▲ 3 | -6.7 percentile points | 30 | Medium confidence | ci-research-gap-v1 | Sep 29, 2026 | showformula: percentile(mortality_count) − percentile(publications_5y)
inputs hash 223409ea4719a317e41b9bc7 Trace lineage (admin) |
| Research Gap Index | USA · Female · all ages · 2024 · top-level cancers | #16 / 28 | ▲ 5 | -3.7 percentile points | 44.4 | Medium confidence | ci-research-gap-v1 | Sep 29, 2026 | showformula: percentile(mortality_count) − percentile(publications_5y)
inputs hash 7e5d4f431c856bc70e0ca539 Trace lineage (admin) |
| Research Gap Index | USA · Male · all ages · 2024 · top-level cancers | #26 / 26 | ▲ 8 | -84 percentile points | 0 | Medium confidence | ci-research-gap-v1 | Sep 29, 2026 | showformula: percentile(mortality_count) − percentile(publications_5y)
inputs hash 164d63cf992b720eb24f77b4 Trace lineage (admin) |
| Research Gap Ratio | USA · both sexes · all ages · 2024 · top-level cancers | #31 / 35 | = | -1.51 log₂ ratio | 11.8 | High confidence | ci-research-gap-ratio-v1 | Sep 29, 2026 | showformula: log2( (deaths / Σ deaths) / (publications_5y / Σ publications_5y) ) over eligible top-level cancers (deaths ≥ 100, publications_5y ≥ 1)
|
| Research Gap Ratio | USA · Female · all ages · 2024 · top-level cancers | #20 / 32 | = | -0.58 log₂ ratio | 38.7 | High confidence | ci-research-gap-ratio-v1 | Sep 29, 2026 | showformula: log2( (deaths / Σ deaths) / (publications_5y / Σ publications_5y) ) over eligible top-level cancers (deaths ≥ 100, publications_5y ≥ 1)
|
| Research Gap Ratio | USA · Male · all ages · 2024 · top-level cancers | #30 / 30 | = | -7.21 log₂ ratio | 0 | Medium confidence | ci-research-gap-ratio-v1 | Sep 29, 2026 | showformula: log2( (deaths / Σ deaths) / (publications_5y / Σ publications_5y) ) over eligible top-level cancers (deaths ≥ 100, publications_5y ≥ 1)
|
| Trial Gap Index | USA · both sexes · all ages · 2024 · top-level cancers | #20 / 31 | = | -3.4 percentile points | 36.7 | Medium confidence | ci-trial-gap-v1 | Sep 29, 2026 | showformula: percentile(mortality_count) − percentile(active_trials)
inputs hash 42c083a5afae5a6aa2195f16 Trace lineage (admin) |
| Trial Gap Index | USA · Female · all ages · 2024 · top-level cancers | #13 / 28 | ▲ 4 | 0 percentile points | 55.6 | Medium confidence | ci-trial-gap-v1 | Sep 29, 2026 | showformula: percentile(mortality_count) − percentile(active_trials)
inputs hash 8bb8392360b97a549e3a1451 Trace lineage (admin) |
| Trial Gap Index | USA · Male · all ages · 2024 · top-level cancers | #26 / 26 | ▲ 10 | -80 percentile points | 0 | Medium confidence | ci-trial-gap-v1 | Sep 29, 2026 | showformula: percentile(mortality_count) − percentile(active_trials)
inputs hash 0d0aad9990c01ec7597b7feb Trace lineage (admin) |
| Trial Gap Ratio | USA · both sexes · all ages · 2024 · top-level cancers | #24 / 35 | = | -0.72 log₂ ratio | 32.4 | High confidence | ci-trial-gap-ratio-v1 | Sep 29, 2026 | showformula: log2( (deaths / Σ deaths) / (active_trials / Σ active_trials) ) over eligible top-level cancers (deaths ≥ 100, active_trials ≥ 1)
|
| Trial Gap Ratio | USA · Female · all ages · 2024 · top-level cancers | #9 / 32 | = | +0.24 log₂ ratio | 74.2 | High confidence | ci-trial-gap-ratio-v1 | Sep 29, 2026 | showformula: log2( (deaths / Σ deaths) / (active_trials / Σ active_trials) ) over eligible top-level cancers (deaths ≥ 100, active_trials ≥ 1)
|
| Trial Gap Ratio | USA · Male · all ages · 2024 · top-level cancers | #30 / 30 | = | -6.4 log₂ ratio | 0 | Medium confidence | ci-trial-gap-ratio-v1 | Sep 29, 2026 | showformula: log2( (deaths / Σ deaths) / (active_trials / Σ active_trials) ) over eligible top-level cancers (deaths ≥ 100, active_trials ≥ 1)
|
Computed Ranks are competition ranks (ties share a rank). Percentile = share of eligible entities ranked at or below this one in the ranking direction.
"Deadliest" is ambiguous: annual deaths, age-standardized mortality rate, mortality-to-incidence ratio and 5-year survival rank cancers differently. CancerIndex publishes each as a separate metric.
inputs hash f271e5ec1a95b0a8843d9337
inputs hash b2d3bb942d1267205c21d786
inputs hash d0a365cf448b4492e5842c02
inputs hash 83b7eb11d6a8211487fc7df9
inputs hash b91f4c1d0fc49c7e7afbbdb1
inputs hash f9abfb651589cac1f9e339e2
inputs hash 9550c89acf4e1815462736d8
inputs hash fb436db47a92ed9d77ca4539
inputs hash 338d8af3f818573f70851946
inputs hash ed85380752fa726a8b46d3a7
inputs hash c534767a0c0d33d01955b651
inputs hash d300e7e394fca651b77ae6c0
inputs hash 00859bd3eb10f4c407191aa0
inputs hash b0a6b56f46e909038d4b0cb2
inputs hash 2ac85be3d921df840476a2d7
inputs hash e52171cf876028dd79f9840c
inputs hash 905414dce6fba7dd9ab9d9de
inputs hash 597d4f521d53739eca953676
Unmet need · computed
ComputedUSA · 2024 · both sexes · all ages · 35 eligible top-level cancerseligible
A gap ratio compares registered activity with deaths inside one scope. It is a signal, not a judgement of research quality; trial counts include NCIt descendants, literature counts are query-based per entity.
Data updated 17 hours agoSource updated unknownscope geo=USA|sex=all|age=all|year=2024|level=top